Connor Clark & Lunn Investment Management Ltd. Sells 81,830 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Connor Clark & Lunn Investment Management Ltd. trimmed its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 46.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,225 shares of the company’s stock after selling 81,830 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.21% of Y-mAbs Therapeutics worth $1,239,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its position in shares of Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after buying an additional 3,416 shares during the period. SG Americas Securities LLC bought a new position in Y-mAbs Therapeutics in the third quarter valued at approximately $178,000. Principal Financial Group Inc. acquired a new stake in Y-mAbs Therapeutics during the 3rd quarter worth $267,000. XTX Topco Ltd bought a new stake in shares of Y-mAbs Therapeutics during the 2nd quarter valued at $297,000. Finally, Caxton Associates LP acquired a new position in shares of Y-mAbs Therapeutics in the 1st quarter valued at $306,000. 70.85% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now owns 67,681 shares of the company’s stock, valued at $877,822.57. This trade represents a 30.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

YMAB has been the topic of a number of recent analyst reports. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. Morgan Stanley decreased their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $21.38.

Y-mAbs Therapeutics Trading Up 2.0 %

NASDAQ:YMAB opened at $10.77 on Wednesday. The firm has a fifty day simple moving average of $13.64 and a 200 day simple moving average of $12.83. Y-mAbs Therapeutics, Inc. has a 1-year low of $5.31 and a 1-year high of $20.90. The stock has a market capitalization of $482.39 million, a PE ratio of -20.07 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period last year, the business earned ($0.18) EPS. On average, equities analysts predict that Y-mAbs Therapeutics, Inc. will post -0.64 earnings per share for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.